Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

27%

3 trials in Phase 3/4

Results Transparency

63%

5 of 8 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 4

3(42.9%)

Phase 2

2(28.6%)

N/A

2(28.6%)

7Total

Phase 4(3)

Phase 2(2)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT04217174Not ApplicableCompleted

An Avatar-based Mobile Phone Intervention to Promote Health in African American MSM

Role: collaborator

NCT01839734Phase 2Completed

Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy

Role: lead

NCT01423812Phase 4Completed

DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects

Role: lead

NCT00775606Phase 4Terminated

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Role: collaborator

NCT03320512Not ApplicableCompleted

P3 (Prepared, Protected, emPowered)

Role: collaborator

NCT03275350Phase 2Completed

Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up

Role: collaborator

NCT04311554Unknown

Aging With Dignity, Health, Optimism and Community

Role: collaborator

NCT01296529Completed

Study on Immunopathogenesis in HIV and Hepatitis C Coinfection

Role: collaborator

NCT00935935Completed

Study of Bone Disease in Older HIV-infected Adults

Role: lead

NCT00227357Completed

The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration

Role: lead

NCT00840762Phase 4Unknown

A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication

Role: lead

All 11 trials loaded